Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Issues in Oncology
Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Dec
22
Today In Oncology
Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma
Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders
MRI First Strategy May Be Safe for Prostate Cancer Detection
Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma
Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Conexiant Oncology Logo